Cefazolin is a semisynthetic first-generation cephalosporin for parenteral administration. Cefazolin has broad-spectrum action due to the inhibition of bacterial cell wall synthesis. It attains high serum levels and its excreted quickly via the urine.
Mechanism of action of cefazolin
In vitro tests demonstrate that the bactericidal action of cephalosporin results from the inhibition of cell wall synthesis. By binding to specific penicillin-binding proteins (PBP) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis.
Cell lysis is then mediated by cell wall autolytic enzymes such as autolysins.
Cefazolin sodium for injection is active against the following organisms in vitro and in clinical infections.
- Staphylococcus aureus including penicillinase-producing strains, staphylococcus epidermidis.
- Group A beta-hemolytic streptococci and other strains of streptococci (many strains of enterococci are resistant).
- Streptococcus pneumoniae
- Escherichia coli
- Klebsiella sp
- Proteus mirabilis
- Haemophilus influenza
- Enterobacter aerogenes
Most strains of indole positive proteus (proteus vulgaris), Enterobacter cloacae, morganella morganii and providentia rettgeri are resistant.
Methicillin-resistant staphylococci, Serratia, Pseudomonas, and Acinetobacter calcoaceticus. (Formerly known as Mima and Herella sp) are most uniformly resistant to cefazolin.
Disc-susceptibility-tests-qualitative methods that require measurement of zone diameters give the most precise estimates of antibiotic susceptibility. One such procedure has been recommended for use with discs for testing susceptibility of cefazolin.
With this procedure, a report from the laboratory about susceptible indicates that the infecting organisms are more likely to respond to the therapy.
A report of resistance indicates that the infecting organisms are not likely to respond to the therapy.
A report of moderately susceptible suggests that the organism would be susceptible if the high dosage is used or if the infection was confirmed to tissues and fluids (eg urine) in which high antibiotic levels are attained.
For gram-positive isolates, a zone of 18 mm is indicative of cefazolin susceptible organism when tested with either the cephalosporin class disc (30 mcg cephalothin) or the cefazolin disc (30 mcg cefazolin).
Gram-negative organisms should be tested with the cefazolin disc (using the above criteria) because cefazolin has been shown by In vitro tests to have activity against certain strains or Enterobacteriaceae found to be resistant when tested with the cephalothin disc. When using the cephalothin disc, gram-negative organisms with zone diameters=18 mm may be considered susceptible to cefazolin; however, organisms with zone diameters less than 18mm are not necessarily resistant or moderately susceptible to cefazolin.
The cefazolin disc should not be used for testing susceptibility to other cephalosporins.
Dilution techniques—A bacterial isolate should be considered susceptible if the minimal inhibitory concentration (MIC) for cefazolin is =16mcg/mL.
organisms are considered resistant if the MIC is=64mcg/Ml.
Clinical pharmacology studies in patients hospitalized with infections indicate that cefazolin produces peak serum levels approximately to those equivalent to those seen in normal volunteers.
In a study (using volunteers) of constant intravenous infusions with dosages of 3.5mg/kg for 1 hour (approximately 250mg) and 1.5 mg/kg for the next 2 hours (approximately 100mg), cefazolin produced a steady serum level at the third hour of approximately 28mcg/Ml. The average serum concentrations after IV injection of a single 1g dose: average half-life was 1.4 hours.
Controlled studies in adult normal volunteers receiving 1 gram four times a day for 10 days, monitoring CBC, AST, ALT bilirubin, alkaline phosphate, BUN, creatinine, and urinalysis indicated no significant changes attributed to cefazolin.
Cefazolin is excreted unchanged in the urine primarily by glomerular filtration and to a lesser degree by tubular secretion. Following intramuscular injection of 500 mg, 56% to 89% of the administered dosage is recovered within 6 hours, and 80% to nearly 100% in 24 hours.
Cefazolin achieves peak urine concentrations greater than 1000mcg/Ml and 4000mcg/mL respectively following 500mg and 1 gram intramuscular doses. In patients undergoing peritoneal dialysis (2L/hr) mean serum levels of cefazolin were approximately 10-30 mcg/Ml after 24 hours of instillation of a dialyzing solution containing 50mcg/Ml and 72 mcg/Ml (26-142 mcg/mL) WITH 150 MCG/Ml.
Intraperitoneal administration of cefazolin is usually well tolerated. When cefazolin is administered to patients with obstructed biliary tracts, high concentrations well above serum levels occur in the gallbladder tissues and bile. In the presence of obstruction, however, the concentration of the serum antibiotic is considerably lower in bile than the serum.
Cefazolin readily crosses the inflamed synovial membrane and the concentration of the antibiotic achieved in joint space is comparable to levels measured in the serum. Cefazolin readily crosses the placental barrier into the cord blood and amniotic fluid. It is present in very low concentrations on the milk of breastfeeding mothers.
Indication of cefazolin
Cefazolin 1 gram injection is indicated in the treatment of the following infections when due to susceptible microorganisms.
Respiratory tract infections such as tonsillitis, pharyngitis, pneumonia, bronchitis, pulmonary abscess, empyema, pleurisy, sinusitis, laryngitis, and otitis media.
Skin, soft tissue infections, and post-operative infections
Lymphangitis, abscesses, cellulitis, decubitus ulcers, mastitis,(surgical procedures should be performed where included).
Gastrointestinal tract infections
Genitourinary tract infections
Pyelonephritis, cystitis, and adnexitis.
Other infections such as bacteremia, septicemia, endocarditis, osteomyelitis, peritonitis, puerperal sepsis.
Patients with hypersensitivity to cephalosporins and their derivatives or any components of their formulations.
Warnings and precautions
Before cefazolin sodium for injection is instituted, a careful inquiry should be made concerning previous hypersensitivity reactions to cephalosporins and penicillins.
Cephalosporin c derivatives should be given cautiously to penicillin-sensitive patients. Serious acute hypersensitivity reactions may require adrenaline and other emergency measures.
There is some clinical and laboratory evidence of partial cross-allergenicity between penicillins and cephalosporins. Patients have been reported to have severe reactions including anaphylaxis to both the classes.
Antibiotics including cefazolin sodium for injection should be administered cautiously to any patient who has demonstrated some form of allergy, particularly to any drugs.
Pseudomembranous colitis has also been demonstrated virtually all broad-spectrum antibiotics such as macrolides, semisynthetic penicillins, and cephalosporins; therefore it's important to consider the diagnosis in patients who develop diarrhea in association with the use of antibiotics. Such colitis may range in severity from mild to life-threatening.
In moderate to severe cases, appropriate measures should be taken. Usage in infants; safety for use in premature and infants under one month of age has not been established.
If an allergic reaction to cefazolin occurs, the medicines should be discontinued and the patient treated with the usual agents eg adrenaline and other pressoramines, antihistamines, or corticosteroids. Prolonged use of cefazolin sodium injection may lead to the overgrowth of nonsusceptible organisms.
Careful clinical observation of the patient is critical.
If superinfection occurs during the therapy, appropriate measures should be taken. When cefazolin sodium for injection is administered to patients with low urinary output because of impaired renal function, a lower dosage is required.
The intrathecal administration of cefazolin sodium for injection is not an approved route of administration for this antibiotic. In fact, there have been reports of severe central venous system toxicity including seizures when cefazolin sodium for injection was administered in this manner.
Broad-spectrum antibiotics should be cautiously prescribed for patients with a history of gastrointestinal disease, particularly colitis.
Carcinogenesis, mutagenesis, and impairment of fertility
Mutagenicity studies and long terms studies in animals to determine the carcinogenic potential of cefazolin sodium for injection have not been performed.
Usage In pregnancy
Preproduction studies have been performed in rats given doses of 500 mg or 1 gram of cefazolin sodium for injection/kg and have revealed no evidence of impaired fertility or harm to the fetus due to cefazolin sodium for injection.
There are however no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this medicine should be used during pregnancy only if clearly needed.
Labour and delivery
When cefazolin sodium injection has been used prior to cesarean section, drug levels in cord blood have been approximately one-fourth to one-third of maternal drug levels. The medication appears to have no adverse effects on the fetus.
Cefazolin sodium for injection is present in very low concentrations in the breast milk of nursing mothers. Caution should be exercised when cefazolin is administered to a nursing woman.
Used concurrently, probenecid may decrease renal tubular secretion of cephalosporins leading to increased and more prolonged cephalosporin blood levels.
A false-positive reaction for glucose in the urine may occur with Benedict's solution, Fehling’s solution, or CLINITEST Tablets, but not with enzyme-based tests, such as CLINISTX and TES-TAPE (Glucose Enzymatic Test Strip, Lilly)
Positive direct and indirect antiglobulin (Coomb’s) tests have occurred; these may also occur in neonates whose mothers received cephalosporins before delivery.
Cefazolin sodium for injection should not be mixed with aminoglycoside antibiotics.
Pregnancy and lactation
Pregnancy category B; Lactation; excreted in breast milk, use with caution.
Dosage and directions for use
The following dosages are recommended for the administration of constituted cefazolin for the injection preferably by intravenous infusion or alternatively by slow intravenous injection (Over 3-5 minutes) or by intramuscular injection.
For the treatment of mild to moderately severe bacterial infections, 1.5 to 2 grams per day in equally divided doses, two or three times daily.
For the treatment of severe bacteremia infections,3-4 grams per day in equally divided doses two to three times daily.
Higher or more frequent doses up to 6 grams daily may be given in severe, life-threatening infections but in rare instances, doses of up to 12 grams have been used.
Percentage of an adult dose
Age and weight
Total daily dose**maximum
Adult (65 kg)
1.5 to 6 g
12 years (40 kg)
1.125 to 4.5 g
7 years (23 kg)
750 mg to 3g
1 year (10 kg)
375 mg to 1.5 g
4 months (6.5 kg)
300 mg to 1.2g
For in-between ages, in between percentiles are used eg at 10 years, 66% and at 3 years 33% of the adult dosage. Using the percentile method based on the following formula
The surface area of a child * 100 =percentage of the adult dosage
The recommended total daily dose should be administered in two to three divided doses. The maximum range is for severe life-threatening infections.
The intravenous route by drip infusion is preferable when high-doses are to be administered. Safety and effectiveness for use in premature infants under one month of age have not been established.
Note that cefazolin for injection may be nephrotoxic if given in excessive doses (more than 6 g daily in patients with normal renal function) or if administered without appropriate dosage reduction in patients with renal impairment. although cefazolin for injection is generally well-tolerated in patients with impaired renal function, it is never the less desirable to adjust the dosage as follows to prevent the accumulation of high blood levels.
Full dose but restricted to at least 8 hr intervals
Half the usual dose every 12 hrs
Half the usual dose every 18-24 hrs
All reduced dosage recommendations apply after an initial loading dose appropriate for the severity of the infection.
Patients undergoing peritoneal dialysis. Treatment should be continued for a minimum of 48-72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained.
For administration by intravenous infusion; use sterile water for injection. Add 2 mL to the 500mg vial and 4 mL to the 1 g vial. Withdraw the entire contents and add to one of the following intravenous solutions
- 0.9% sodium chloride injection
- 5% to 10% dextrose injection
- 5% dextrose in ringers injection
- 5% dextrose in 0.9% sodium chloride injection (also may be used with 5% dextrose and 0.45% or 0.2% sodium chloride injection).
- Lactated ringers solution
- 5% or 10% invert sugar in sterile water for injection.
- Ringers injection
For administration via direct intravenous injection
After the constitution with 2 ml water for injection in 500mg or 4 ml water for injection in 1 gram, dilute with 10mL of water for injection. Inject solution slowly over 3-5 minutes either by directly into a vein or through a tubing in patients receiving the parenteral fluids.
For administration by intramuscular injection; add 2 ml (500mg) or 4 ml (1 gram) of sterile water for injection, bacteriostatic water for injection, or 0.9% normal saline. Withdraw all the entire contents to the vial.
The constituted solution is stable for administration for 24 hours when kept at room temperature not exceeding 25 degrees Celcius or for 96 hours when kept in a refrigerator (4-8 degrees).
Side effects of cefazolin
Cefazolin for injection has the potential for producing hypersensitivity reactions such as rash, pruritus, urticaria, angioedema, eosinophilia, drug fever, and anaphylaxis.
Leukopenia, neutropenia, thrombocytopenia, positive direct, and indirect Coomb’s test have been reported.
A transient rise in AST, ALT, and alkaline phosphatase levels have been observed rarely. Transient hepatitis and cholestatic jaundice have been reported.
A transient rise in blood urea levels has been observed without aclinical evidence of renal impairment. interstitial nephritis and other renal disorders have been reported rarely.
Most patients experiencing these reactions had been seriously ill and were receiving multiple drug therapies. The role of cefazolin in the development of nephropathies has not been fully determined.
Symptoms of pseudomembranous colitis may appear either during or after antibiotic therapy. Nausea and vomiting have been reported. Anorexia, diarrhea, and oral candidiasis have been reported.
Other side effects;
Pain on the injection site, tenderness, and induration fever,
Genial and anal pruritis, genital candidiasis and vaginitis.
Severe central nervous system toxicity ie seizures when administered intrathecally.
Known symptoms of overdosage and treatment
Inappropriately large doses may cause dizziness, paraesthesias, and headache.
Seizures may occur following overdose with some cephalosporins, particularly in patients with renal impairment in whom accumulation is likely to occur. Dosage reduction is necessary when renal function is impaired.
If seizures occur the drug should be promptly discontinued; anticonvulsant therapy may be administered if clinically indicated. Hemodialysis may be considered in cases of overwhelming overdosage.
Laboratory abnormalities that may occur after an overdose include elevations in creatinine, BUN, liver enzymes and bilirubin, a positive Coomb’s tests, thrombocytopenia, thrombocytosis, eosinophilia, leukopenia, and prolongation of the prothrombin time.
Treatment of overdosage should be asymptomatic and supportive.